Axsome Therapeutics price target raised to $140 from $138 at RBC Capital
RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $140 from $138 and keeps an Outperform rating on the shares as part ...
Axsome Therapeutics: Strong Buy Recommendation Driven by Promising Pipeline and Market Expansion
Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...
BioSpace6d
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...
Yahoo Finance6d
Axsome Therapeutics, Inc. (AXSM)
Details for the presentations are as follows: Majo NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel ...
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome.
In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...
alzheimersnewstoday5d
Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...
Yahoo Finance2d
Axsome Therapeutics, Inc. (AXSM)
At close: January 2 at 4:00:01 PM EST ...
pharmaphorum1d
Axsome bounces back as FDA clears depression drug
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...
The Pharma Letter3d
Axsome Therapeutics
Axsome’s bid to market its option in Alzheimer’s disease, an area which has gained renewed interest thanks to the recent launch of novel therapeutics for the first time in decades, comes after US ...
Yahoo Finance5d
Axsome Therapeutics, Inc. (AXSM)
After hours: January 3 at 7:39:57 p.m. EST ...